A Smart + Strong Site
Subscribe to:
Newsletters
POZ magazine
JOIN AIDSMEDS YouTube

Back to home » Treatment News » Top Stories

Most Popular Stories
Undetectable Viral Load Essentially Eliminates Transmission Risk in Straight Couples
FDA Approves New Single-Tablet HIV Regimen, Triumeq
Life Expectancy for Young People With HIV Is Nearly Normal
A 15-Year Jump in Life Expectancy for People With HIV
Scientists Devise Method of Snipping HIV From Immune Cells
Monkey HIV Vaccine Success Opens Door for Human Trials
HIV Combo Pill Less Toxic Thanks to New Form of Tenofovir
What's That Mean?
(just double-click it!)

If you don't understand one of the words in this article, just double-click it. A window will open with a definition from mondofacto's On-line Medical Dictionary. If the double-click feature doesn't work in your browser, you can enter the word below:

Most Popular Lessons
Aging & HIV
The HIV Life Cycle
Shingles
Herpes Simplex Virus
Syphilis & Neurosyphilis
Treatments for Opportunistic Infections (OIs)
What is AIDS & HIV?
More News

Have medical or treatment news about HIV? Send press releases, news tips and other announcements to news@aidsmeds.com.

Click here for more news


emailprint

August 28, 2012

Activists Protest Stribild's $28,500 Price Tag

by Tim Horn

The Fair Pricing Coalition and other activists are taking Gilead Sciences to task for what they say is an exorbitant per-patient annual wholesale acquisition cost (WAC) for Striblid (elvitegravir plus cobicistat, tenofovir and emtrictabine), the fixed-dose combination tablet formerly known as the 'Quad' approved by the U.S. Food and Drug Administration on Monday, August 27.

In a news announcement released Tuesday, August 28, the coalition of activists who work on HIV and viral hepatitis drug pricing issues “strongly protests” the $28,500 WAC announced by Gilead. And in the hours following the drug's approval, Simon Collins of the U.K.-based HIV i-base penned an article indicating that "the expected welcome for an important new option for treatment has been firmly squashed by the indication that Gilead plan to market [Stribild] at a price that will exclude access for most HIV-positive patients in Europe."

 “This is a long-anticipated addition to the options available to people living with HIV/AIDS and their healthcare providers”, echoed Lynda Dee, a Fair Pricing Coalition spokesperson. “However, in pricing the new drug more than 35 percent above the $21,000 per-year WAC price of its own best-selling single-tablet regimen, Atripla [efavirenz plus tenofovir and emtricitabine], Gilead has created an environment of restricted access and financial hardship for patients impacted by current dire economic conditions and U.S. healthcare costs and whose very lives depend on access to more convenient treatments.”  

The Fair Pricing Coalition believes Gilead is pricing cobicistat, its own booster component of Stribild, comparably with Abbott Laboratories’ Norvir [ritonavir], “which includes Abbott’s unconscionable 400 percent price increase” while its closest competitor Merck & Co.’s integrase inhibitor Isentress (raltegravir), plus Truvada (tenofovir plus emtricitabine), needs no booster and has an annual WAC of $26,200.  

Thus, Dee and her colleagues suggest, “Stribild’s booster component cobicistat is more like excess baggage than an achievement worth $2,000 above the only other approved integrase inhibitor combination.” They add that there may also be a greater risk of kidney side effects with Stribild than with the Merck integrase inhibitor combination.    

"The strategic decision to price [Stribild] beyond the reach of most people threatens to undermine Gilead’s reputation with doctors, researchers, patients and ultimately shareholders," Collins wrote. "The easiest way to recoup investment costs for development of a new drug is to price it at a level where it will be widely used. The underlying greed from the current proposed price will make it impossible for activists to argue for patient choice when scarce funding is merely being diverted to pharmaceutical profits. Ultimately, from 27 August onwards, most people in Europe are likely to continue on existing treatments only, and new approvals will become only aspirational care, lanquishing underutilized until their patent expires, just after the announcement of a cure."

“Gilead asked for community input in setting the price of its new product, and invited the Fair Pricing Coaltion to the negotiating table in June for discussions,” said Dee.  “We thought we had reached a reasonable understanding with Gilead, but evidently the company is more interested in filling its coffers than in reasonable and fair pricing.  I’m shocked at the price they have set, and would call this a betrayal of the spirit of our negotiations.“

Search: hiv, stribild, quad, elvitegravir, cobicistat, tenofovir, emtricitabine, truvada, atripla, norvir, price, wac, wholesale acquisition cost, fair pricing coalition, fpc, lynda dee


Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The AIDSmeds team reviews all comments before they are posted. Please do not include ":" "@" "<" ">" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Show comments (13 total)


[Go to top]

Quick Links
About HIV and AIDS
The Cure
Lab Tests
Clinical Trials
HIV Meds
Starting Treatment
Switching Treatment
Drug Resistance
Side Effects
Disclosure
Lipodystrophy
Hepatitis & HIV
Women & Children
Fact Sheets
Treatment News
Community Forums
Blogs
Conference Coverage
Health Services Directory
POZ Magazine


    chipper52
    Palm Springs
    California


    slimcuteguy
    Asheville
    North Carolina


    youngbloodlatino
    Columbia
    Maryland


    RayOctober
    Richmond
    Virginia
Click here to join POZ Personals!
Conference Coverage

XX International AIDS Conference
(AIDS 2014)
Melbourne, Australia
July 20 - 25, 2014


21st Conference on Retroviruses and Opportunistic Infections
(CROI 2014)
Boston, MA
March 3 - 7, 2014


7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention
(IAS 2013)
Kuala Lumpur, Malaysia
June 30 - July 3, 2013


more conference coverage

[ about AIDSmeds | AIDSmeds advisory board | our staff | advertising policy | advertise/contact us]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.